Cargando…

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma

BACKGROUND: Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our obj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Lifen, Ren, Zhenggang, Jia, Qingan, Wu, Weizhong, Shen, Hujia, Wang, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734040/ https://www.ncbi.nlm.nih.gov/pubmed/23895220 http://dx.doi.org/10.1186/1471-2407-13-363

Ejemplares similares

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study
por: Zhang, Zhe, et al.
Publicado: (2009)

Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
por: Liu, Jianhua, et al.
Publicado: (2017)

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
por: Li, Qiaoqiao, et al.
Publicado: (2012)

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma
por: Sho, Takuya, et al.
Publicado: (2017)

Treatment with the herbal formula Songyou Yin inhibits epithelial-mesenchymal transition in hepatocellular carcinoma through downregulation of TGF-β1 expression and inhibition of the SMAD2/3 signaling pathway
por: Zheng, Susu, et al.
Publicado: (2017)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

The Synergistic In Vitro and In Vivo Antitumor Effect of Combination Therapy with Salinomycin and 5-Fluorouracil against Hepatocellular Carcinoma
por: Wang, Fan, et al.
Publicado: (2014)

Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018)

Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells
por: Wu, Man, et al.
Publicado: (2018)

Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)

OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53
por: Omar, Hany A., et al.
Publicado: (2016)

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis
por: Liu, Zhi-Yong, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study
por: Yuan, Jia, et al.
Publicado: (2019)

Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma
por: GUO, XU-FENG, et al.
Publicado: (2015)

Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
por: Seyhoun, Iman, et al.
Publicado: (2019)

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Synergistic antitumor effect of resveratrol and sorafenib on hepatocellular carcinoma through PKA/AMPK/eEF2K pathway
por: Gao, Meili, et al.
Publicado: (2021)

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma
por: He, Yuchao, et al.
Publicado: (2023)

Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
por: Bort, Alicia, et al.
Publicado: (2017)

Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018)

Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
por: Kano, Y., et al.
Publicado: (1996)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

Synergistic antitumor effects of tanshinone IIA and sorafenib or its derivative SC-1 in hepatocellular carcinoma cells
por: Chiu, Chien-Ming, et al.
Publicado: (2018)

Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma
por: Ho, Chun-Ming, et al.
Publicado: (2022)

Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer
por: Tong, Jingtao, et al.
Publicado: (2011)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
por: Liu, Kai-Cai, et al.
Publicado: (2020)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
por: Gao, Xudong, et al.
Publicado: (2019)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells
por: Cai, Hongqiao, et al.
Publicado: (2019)

Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma
por: Wang, Bin, et al.
Publicado: (2021)

Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
por: Wild, Aaron T., et al.
Publicado: (2013)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lf5l51691jmm40lpnr3pgk9n4s